Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth

Fig. 5

Long-term tasquinimod treatment reduces the tumor-induced expansion of splenic myeloid cells. BALB/c mice were inoculated with 105 4 T1 cells s.c. Tasquinimod (25 mg/kg/day) was given in the drinking water during the indicated time points. Spleens were collected 14 days post-inoculation, weighed and spleen cells analyzed by flow cytometry. a, Spleen weight (left) and representative image of the spleens (right) at day 14 post-inoculation (naïve, n = 4; ctrl, n = 7; tasq 0–7, n = 7; tasq 0–14, n = 6). b, Frequency of splenic CD11b+, Ly6Chi, Ly6Ghi and SiglecF+ cells gated from total viable or CD11b+ CD19 cells. c, Representative FACS plots showing the gating of splenic c-kit+ Sca1 and c-kit+ Sca1+ cells within the Lin cell population. d, Frequency of splenic c-kit+ Sca1 and c-kit+ Sca1+ cells gated from Lin cells (naïve, n = 3; ctrl, n = 7; tasq 0–14, n = 6). Representative results of at least two independent experiments are shown for all experimental settings. n.s. = not significant, *P < 0.05, **P < 0.01, Mann–Whitney U-test

Back to article page